Population pharmacokinetics and pulmonary modeling of eravacycline and the determination of microbiological breakpoint and cutoff of PK/PD
Antimicrobial Agents and Chemotherapy · 05.03.2025 · 69 (3)
DOI: 10.1128/aac.01065-24 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 05.03.2025. Verfasst von Xi-Wei Ji und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Pharmacology, Peking University First Hospital, Beijing, China. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Tetracyclines, Lung. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fudan University (), Shanghai Municipal Health Commision Clinical Research Youth Project.
Abstract (Originalsprache)
Eravacycline is a broad-spectrum fluorocycline currently approved for complicated intra-abdominal infections (cIAIs). In lung-infection models, it is effective against methicillin-resistant Staphylococcus aureus (MRSA) and tetracycline-resistant MRSA. As such, we aimed to develop a population pharmacokinetic/pharmacodynamic (PK/PD) model to evaluate eravacycline’s pulmonary distribution and kinetics. Data were extracted from a Phase I study ( NCT01989949 ) which assessed the bronchopulmonary disposition of intravenous eravacycline to construct the population PK model that could adequately describe the drug’s pulmonary kinetics. Eravacycline lung PK was best described by a three-compartment model with allometric scaling, with the epithelial lining fluid (ELF) component parameterized as the ELF distribution ratio ( R a t i o = C f r e e , E L F C f r e e , c e n t r a l , unbound concentration in ELF over central compartment). The estimated ELF distribution ratio was 8.26 (95% confidence interval = 6.8–9.8). Besides allometrically scaled weight, no other significant covariate was found. MIC 90 was 0.5 mg/L ( Escherichia coli ), 2 mg/L ( Klebsiella pneumoniae ), 0.5 mg/L ( Acinetobacter baumannii ), and 0.12 mg/L ( S. aureus ). At the approved cIAI dosage or higher (1 mg/kg or 1.5 mg/kg q12h), a PK/PD cutoff value of 2 mg/L was appropriate for E. coli , while a lower value of 1 mg/L was selected for K. pneumoniae , A. baumannii , and S. aureus . For lower doses, the cutoff value was reduced to 0.5 mg/L for K. pneumoniae , A. baumannii , and S. aureus . The study showed eravacycline was widely distributed into the lungs with promising antibacterial efficacy, thus justifying further investigations into its uses for pulmonary infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Clinical Pharmacology, Peking University First Hospital, Beijing, China.
- Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai, China.
- Momentum Metrix, San Francisco, California, USA.
ORCID-Profile: Wen Yao Mak, Yun Li, Xiao Zhu
Förderung
- Fudan University ()
- Shanghai Municipal Health Commision Clinical Research Youth Project
Zitieren
APA
Ji, X., Mak, W. Y., Xue, F., Yang, W., Kuan, I. H. S., Xiang, X., Li, Y., & Zhu, X. (2025). Population pharmacokinetics and pulmonary modeling of eravacycline and the determination of microbiological breakpoint and cutoff of PK/PD. Antimicrobial Agents and Chemotherapy, 69(3). https://doi.org/10.1128/aac.01065-24
Vancouver
Ji X, Mak WY, Xue F, Yang W, Kuan IHS, Xiang X, et al. Population pharmacokinetics and pulmonary modeling of eravacycline and the determination of microbiological breakpoint and cutoff of PK/PD. Antimicrobial Agents and Chemotherapy. 2025;69(3). doi:10.1128/aac.01065-24
BibTeX
@article{Ji2025,
author = {Ji, Xi-Wei and Mak, Wen Yao and Xue, Feng and Yang, Wen-Yu and Kuan, Isabelle Hui-San and Xiang, Xiao-Qiang and Li, Yun and Zhu, Xiao},
title = {Population pharmacokinetics and pulmonary modeling of eravacycline and the determination of microbiological breakpoint and cutoff of PK/PD},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
volume = {69},
number = {3},
doi = {10.1128/aac.01065-24}
}
EUVIMED